{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:58:20Z","timestamp":1792497500667,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.molmed.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:27:25Z","timestamp":1725899245000},"page":"209-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Harnessing the immune system: vaccines to fight neurodegenerative diseases"],"prefix":"10.1016","volume":"31","author":[{"given":"Alba","family":"Gonzalez-Artero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Pujols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9652-6351","authenticated-orcid":false,"given":"Salvador","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.08.005_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.08.005_bb0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","article-title":"Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease","volume":"10","author":"Sekiya","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.molmed.2024.08.005_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.molmed.2024.08.005_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.08.005_bb0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2024.08.005_bb0030","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.08.005_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.08.005_bb0040","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer\u2019s disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.molmed.2024.08.005_bb0045","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.molmed.2024.08.005_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","author":"Eijsvogel","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.08.005_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.molmed.2024.08.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine \u2013 a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.08.005_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies \u2013 implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.molmed.2024.08.005_bb0070","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1073\/pnas.1001740107","article-title":"Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering","volume":"107","author":"Sandberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.08.005_bb0075","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424002193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424002193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:06:04Z","timestamp":1741777564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424002193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1471491424002193"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.08.005","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the immune system: vaccines to fight neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}